Consolidation Chemotherapy

Drug treatment designed to further diminish the disease toward complete remission following INDUCTION CHEMOTHERAPY. It helps to consolidate the gains during induction chemotherapy and may be followed by MAINTENANCE CHEMOTHERAPY.

Also Known As:

Networked: 631 relevant articles (138 outcomes, 146 trials/studies)

Relationship Network

Therapy Context: Research Results

Experts

1.	Stone, Richard M: 6 articles (01/2020 - 07/2011)
2.	Sierra, Jorge: 5 articles (11/2020 - 08/2004)
3.	Thomas, Xavier: 5 articles (12/2018 - 02/2007)
4.	Garcia-Aguilar, Julio: 4 articles (10/2022 - 10/2015)
5.	Esteve, Jordi: 4 articles (01/2022 - 02/2003)
6.	Fietkau, Rainer: 4 articles (01/2022 - 04/2006)
7.	Kanda, Yoshinobu: 4 articles (01/2022 - 01/2010)
8.	Vrdoljak, Eduard: 4 articles (11/2021 - 03/2005)
9.	Adamsen, Lis: 4 articles (09/2021 - 02/2013)
10.	Jarden, Mary: 4 articles (09/2021 - 02/2013)

Related Diseases

1.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 11/01/2019 - "Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study." 03/15/2014 - "The objective of the current study was to investigate the role of postremission consolidation chemotherapy before reduced-intensity conditioning (RIC) allogeneic stem cell transplantation (alloSCT) for patients with acute myeloid leukemia (AML) in first complete remission (CR1). " 08/05/2023 - "Although the need for consolidation chemotherapy after successful induction therapy is well established in patients with acute myeloid leukemia (AML) in first complete remission (CR1), the value of consolidation chemotherapy before allogeneic hematopoietic stem cell transplantation remains controversial. " 01/01/2021 - "CORRIGENDUM to "Should patients receive consolidation chemotherapy before reduced intensity allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia in first complete remission?"" 01/01/2021 - "For acute myeloid leukemia (AML) patients, the role of bridging consolidation chemotherapy after achieving first complete remission (CR1) in the transplant setting is a frequently debated issue. "
2.	Leukemia 03/01/1985 - "These data show that bone marrow transplantation is more effective than consolidation chemotherapy in preventing leukemia relapse, but overall survival was not improved in this study." 01/01/2019 - "Currently, the post-remission treatment in acute leukemia is based on the genetic profile of leukemic cells at diagnosis (ie, FLT3 ITD positivity) and on the level of measurable residual disease (MRD) after induction and consolidation chemotherapy. " 01/01/1976 - "Early consolidation chemotherapy for adults with acute leukemia in remission." 01/01/2016 - "Multimodal intervention integrated into the clinical management of acute leukemia improves physical function and quality of life during consolidation chemotherapy: a randomized trial 'PACE-AL'." 02/01/2013 - "This study investigates the feasibility, safety and benefits of a 6-week exercise and health counseling intervention in patients with acute leukemia undergoing consolidation chemotherapy during outpatient management. "
3.	Neoplasms (Cancer) 04/01/2007 - "Complete remission (CR) was achieved after induction and consolidation chemotherapy (Children's Cancer Study Group 1891 protocol, CCG1891). " 09/01/2021 - "He was started on induction and subsequent consolidation chemotherapy with complete remission and shrinkage of the tumor." 01/01/1993 - "Twelve adults with haematological malignancies received consolidation chemotherapy of complete remission. " 01/01/2020 - "The consolidation chemotherapy group improved pCR rate (19.3% vs 4.9%, p = 0.01) and tumor downstaging rate (45.8% vs 24.6%, p = 0.009) compared to the standard treatment group. " 08/01/2014 - "Modern treatment protocols utilizing intense induction followed by myeloablative consolidation chemotherapy with autologous stem cell rescue (ASCR) have improved survival rates, but the long-term sequelae, including development of secondary malignant neoplasms (SMN), are just now surfacing. "
4.	Acute Promyelocytic Leukemia 01/01/2017 - "Currently, the optimal maintenance therapy for patients with acute promyelocytic leukemia (APL) who have achieved complete remission (CR) after completing consolidation chemotherapy remains controversial. " 12/01/2012 - "The optimal maintenance therapy for patients with acute promyelocytic leukemia (APL) who achieved complete remission (CR) and complete consolidation chemotherapy is still controversial. " 06/01/2005 - "Durable molecular remissions with a single cycle of timed sequential consolidation chemotherapy in acute promyelocytic leukemia." 04/01/1999 - "The feasibility and safety of outpatient management of acute promyelocytic leukemia (APL) during the aplastic phase after intensive consolidation chemotherapy, the incidence and types of complications requiring readmission to hospital, and the number of hospital days spared by this policy have been prospectively evaluated. " 04/01/1999 - "Outpatient management of acute promyelocytic leukemia after consolidation chemotherapy."
5.	Residual Neoplasm 06/01/2022 - "The remission rate before consolidation chemotherapy between the two groups was not significantly different (P=0.198), but the negative conversion rate of minimal residual disease (MRD) in CCLG-ALL 2008 group was significantly higher than that in CCCG-ALL 2015 group (P=0.000). " 05/14/2021 - "Among the 11 patients with TP53 gene mutation who relapsed during consolidation chemotherapy, 6 received anti-CD19 CAR T cell therapy, 4 patients achieved remission and minimal residual disease (MRD) turned negative, followed by bridging allo-HSCT, and 2 of them sustained CR. " 11/01/2003 - "A total of 31 adult patients with AML entered in the EORTC/GIMEMA AML-10 trial, who received autologous stem cell transplantation (ASCT) after induction and consolidation chemotherapy, were prospectively evaluated for minimal residual disease (MRD) by multidimensional flow cytometry (MFC). " 08/05/2023 - "Pre-transplantation minimal residual disease-negative patients with AML in CR1 who received MSDT with ≥ 3 courses of consolidation chemotherapy had a higher probability of LFS (85.9% vs . " 01/01/2021 - "The loss or absence of minimal residual disease of <0·1% at any time after two cycles of consolidation chemotherapy in CBFB-MYH11-positive acute myeloid leukaemia indicates poor prognosis."

Related Drugs and Biologics

1.	Cytarabine (Cytosar-U)
2.	Cisplatin (Platino)
3.	Daunorubicin (Cerubidine)
4.	Granulocyte Colony-Stimulating Factor (G-CSF)
5.	Mitoxantrone (Novantrone)
6.	Tretinoin (Retinoic Acid)
7.	Paclitaxel (Taxol)
8.	Arsenic Trioxide (Trisenox)
9.	Carboplatin (JM8)
10.	Docetaxel (Taxotere)

Related Therapies and Procedures

1.	Therapeutics
2.	Radiotherapy
3.	Hematopoietic Stem Cell Transplantation
4.	Drug Therapy (Chemotherapy)
5.	Cell Transplantation